Stock Watch: New Year, New Politics; Same Old Pricing And Generic Challenges
And Amarin Rallies Despite Unpromising Prospects
A positive start to the year for healthcare stocks was accompanied, as usual, by drug price increases. This and the other issues that have been carried over from 2020 remain just as challenging.
You may also be interested in...
The European Medicines Agency has recommended in favor of approval for Amarin’s fish-oil derivative, Vazkepa.
The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.